Table 1. Characteristics and clinical... | American Society of Hematology

Table 1.

Characteristics and clinical outcomes of patients treated on the phase 1 clinical trial

Patient	Age, y	Sex	Diagnosis	Disease characteristics	Disease status at SCT	MRD	Relapse risk	Donor	Engraftment	Time to ANC 500	Chimerism at day 28	Grade 2-4 aGVHD	Grade 3-4 aGVHD	Systemic steroids	cGVHD	Outcome of SCT	Last follow-up
1	40	M	CML	Refractory to TKIs	CP1	−	Int	Son	Yes	20	Mixed	No	No	No	No	Died (TRM)	Day +85
2	52	F	AML	FLT3⁺	Relapse pretransplant	+	High	Son	Yes	17	Donor	Yes	No	Yes	No	Relapsed	Day +582
3	60	M	CML, MDS	Monosomy 7	CP1	−	High	Daughter	Yes	27	Donor	Yes	No	No	No	Remission	Day +755
4	38	F	AML	PIF, cx. cyto, MLL⁺	CR1	+	High	Sister	Yes	16	Donor	No	No	No	No	Remission	Day +410
5	43	M	AML	PIF, diploid cyto	CR1	−	High	Brother	Yes	18	Donor	Yes	No	Yes	No	Remission	Day +419
6	34	M	CML	BP CNS⁺	CP2	−	High	Sister	Yes	21	Donor	No	No	No	No	Remission	Day +481
7	23	M	AML	FLT3⁺	CR1	−	High	Sister	Yes	15	Donor	No	No	No	No	Remission	Day +417
8	18	F	AML	ASXL1⁺	CR1	+	High	Father	Yes	21	Donor	Yes	No	Yes	No	Remission	Day +316
9	58	F	AML	MLL⁺	CR1	−	High	Daughter	Yes	19	Donor	Yes	No	No	No	Remission	Day +412
10	45	F	CML	BP CNS⁺	CP2	−	High	Brother	Yes	19	Donor	Yes	No	Yes	No	Remission	Day +477
11	55	M	AML	MLL⁺	CR1	+	High	Son	Yes	14	Donor	No	No	No	No	Remission	Day +448
12	25	F	AML	PIF, diploid cyto	CR1	−	High	Sister	Yes	17	Donor	Yes	No	Yes	No	Remission	Day +363
13	48	F	CML	Refractory to TKIs	CP1	+	Int	Daughter	Yes	19	Donor	No	No	No	No	Remission	Day +236

Patient	Age, y	Sex	Diagnosis	Disease characteristics	Disease status at SCT	MRD	Relapse risk	Donor	Engraftment	Time to ANC 500	Chimerism at day 28	Grade 2-4 aGVHD	Grade 3-4 aGVHD	Systemic steroids	cGVHD	Outcome of SCT	Last follow-up
1	40	M	CML	Refractory to TKIs	CP1	−	Int	Son	Yes	20	Mixed	No	No	No	No	Died (TRM)	Day +85
2	52	F	AML	FLT3⁺	Relapse pretransplant	+	High	Son	Yes	17	Donor	Yes	No	Yes	No	Relapsed	Day +582
3	60	M	CML, MDS	Monosomy 7	CP1	−	High	Daughter	Yes	27	Donor	Yes	No	No	No	Remission	Day +755
4	38	F	AML	PIF, cx. cyto, MLL⁺	CR1	+	High	Sister	Yes	16	Donor	No	No	No	No	Remission	Day +410
5	43	M	AML	PIF, diploid cyto	CR1	−	High	Brother	Yes	18	Donor	Yes	No	Yes	No	Remission	Day +419
6	34	M	CML	BP CNS⁺	CP2	−	High	Sister	Yes	21	Donor	No	No	No	No	Remission	Day +481
7	23	M	AML	FLT3⁺	CR1	−	High	Sister	Yes	15	Donor	No	No	No	No	Remission	Day +417
8	18	F	AML	ASXL1⁺	CR1	+	High	Father	Yes	21	Donor	Yes	No	Yes	No	Remission	Day +316
9	58	F	AML	MLL⁺	CR1	−	High	Daughter	Yes	19	Donor	Yes	No	No	No	Remission	Day +412
10	45	F	CML	BP CNS⁺	CP2	−	High	Brother	Yes	19	Donor	Yes	No	Yes	No	Remission	Day +477
11	55	M	AML	MLL⁺	CR1	+	High	Son	Yes	14	Donor	No	No	No	No	Remission	Day +448
12	25	F	AML	PIF, diploid cyto	CR1	−	High	Sister	Yes	17	Donor	Yes	No	Yes	No	Remission	Day +363
13	48	F	CML	Refractory to TKIs	CP1	+	Int	Daughter	Yes	19	Donor	No	No	No	No	Remission	Day +236

AML, acute myeloid leukemia; ANC, absolute neutrophil count; BP, blast phase; CML, chronic myeloid leukemia; CNS, central nervous system; CP1, chronic phase 1; CP2, chronic phase 2; CR1, first complete remission; CR2, second complete remission; cx., complex; cyto, complex cytogenetics; F, female; FLT3, FMS-like tyrosine kinase 3; GVHD, graft-versus-host disease; Int, intermediate; M, male; MDS, myelodysplastic syndrome; MLL, mixed lineage leukemia gene; MRD, minimal residual disease; PIF, primary induction failure; SCT, stem cell transplant; TKI, tyrosine kinase inhibitor.

View Large

This Feature Is Available To Subscribers Only